Clinical Trials
83 trialsLisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sun Yat-sen University
STARLING
Indiana University
Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
IASO207 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Peking University People's Hospital
QiNKT-HSCT
University Hospital Pilsen
ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
Fondazione Italiana Linfomi - ETS
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
Shanghai Jiao Tong University School of Medicine
Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer
National Cancer Institute, Egypt
A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies
Kousai Bio Co., Ltd.
Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies
Institute of Hematology & Blood Diseases Hospital, China
STRAP
National Cancer Centre, Singapore
CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences
EpiRev-NKT
Fudan University
Predicting Recurrence in HR+/HER2- Early Breast Cancer
Shengjing Hospital
EINSTEIN-TNBC
Sunnybrook Health Sciences Centre
PRiME II
Washington University School of Medicine
EPPIL
Institut Jean-Godinot
EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
Huazhong University of Science and Technology
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia
University of Rochester
A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
SL4903
Institute of Hematology & Blood Diseases Hospital, China
CALM-TF
University Health Network, Toronto
A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer
Zhongnan Hospital
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
Tongji Hospital
Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Tongji Hospital
Mezi-KD
Assistance Publique - Hôpitaux de Paris
Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors
The First Affiliated Hospital with Nanjing Medical University
GABRIEL
Medical College of Wisconsin
125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors
Jinan Military General Hospital
A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
Affiliated Hospital of Jiangsu University
Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT
Peking University People's Hospital
A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies
Affiliated Hospital of Jiangsu University
BaseCAR-01
University Hospital, Basel, Switzerland
Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Sun Yat-sen University
Penfluridol for Relapsed/Refractory Small Cell Cancers
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms
Institute of Hematology & Blood Diseases Hospital, China
GEM-IR-NMIBC
Shanghai University of Traditional Chinese Medicine
HEM-iSMART E
Princess Maxima Center for Pediatric Oncology
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
Nationwide Children's Hospital
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
The First Affiliated Hospital with Nanjing Medical University
Adjuvant
Shanghai Pulmonary Hospital, Shanghai, China
Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery
Guangzhou University of Traditional Chinese Medicine
CAR19BCMA
Chinese PLA General Hospital
Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection
Tongji Hospital
Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial
National Taiwan University Hospital
Three Times Weekly Symptom Screening for Children With Cancer
The Hospital for Sick Children